VICO invests an additional US$60 million in its ASO platform

Márcio
Jan 5, 2024
1 min read

Excellent news, released today (January 5th). VICO Therapeutics, a Dutch company that is testing ASO gene therapy (VO659) for the ataxias SCA1 and SCA3, and also for Huntington's disease (HD), has just announced that it has invested an additional US$60 million to ensure the continuity of research.

Learn more at

https://www.investorsobserver.com/news/qm-pr/4698887309906511?fbclid=IwAR2ER1hzTD0ZYvvwQWvCpEf9pdK9vschKy8lQwB8x1-WcStMzKwOfV1xtPg_aem_Afchbb98BG-Ql9J-tyZsCcAYdFdFF8P1OPQnVm5PBh0e5WskFpovJMmWVwHiabPoi08&fs=e&s=cl

[Post published on 01/05/2024 by Márcio Galvão]